Kaempferol, Luteolin, Astragalin, and Tiliroside Change Glycoform Expression in HT-29 and DLD-1 Colon Cancer Cells
Biomolecules · 18.11.2026 · 16 (11) · 1676
DOI: 10.3390/biom16111676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 18.11.2026. Verfasst von Karolina Czerwińska und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok.
Abstract (Originalsprache)
This study examined the impact of the polyphenols kaempferol, luteolin, astragalin, and tiliroside on glycoforms in HT-29 and DLD-1 colon cancerous cells at concentrations of 80 and 160 μM. qRT-PCR was used to assess the mRNA of the examined factors. For protein determination, Western blotting was used, and the expression of carbohydrate antigens was examined via ELISA. MUC1, ppGalNAcT2, ST6GalNAcT2, C1GalT1, ST3GalT1, FUT3/4 mRNAs, Tn, sialyl Tn, sialyl T, and Fucα1,3-GlcNAc epitopes were inhibited by all examined polyphenols in both cell lines. Cosmc mRNA was inhibited by all compounds in DLD-1 cells and by luteolin, astragalin, and tiliroside in HT-29 cells. Gal-3 mRNA was only unchanged after tiliroside pretreatment in HT-29 cells. Extracellular domains of MUC1 in HT-29 were inhibited by luteolin, astragalin, tiliroside, and kaempferol had no effect on the 135 kDa unit. In DLD-1 cells, kaempferol and astragalin suppressed these MUC1 domains. Luteolin did not influence the 245 kDa subunit, and tiliroside increased the expression of this domain. The C1GalT1 protein was suppressed by luteolin and tiliroside in HT-29 cells and by kaempferol, luteolin, and astragalin in DLD-1. T-antigen expression was inhibited by all compounds in HT-29 cells; in DLD-1, tiliroside had no impact on this antigen. Our findings indicate the potential use of the studied polyphenols as therapeutic agents in colon cancer.
Förderung
- Medical University of Białystok
Zitieren
APA
Czerwińska, K., Bielawska, A., & Radziejewska, I. (2026). Kaempferol, Luteolin, Astragalin, and Tiliroside Change Glycoform Expression in HT-29 and DLD-1 Colon Cancer Cells. Biomolecules, 16(11), 1676. https://doi.org/10.3390/biom16111676
Vancouver
Czerwińska K, Bielawska A, Radziejewska I. Kaempferol, Luteolin, Astragalin, and Tiliroside Change Glycoform Expression in HT-29 and DLD-1 Colon Cancer Cells. Biomolecules. 2026;16(11):1676. doi:10.3390/biom16111676
BibTeX
@article{Czerwiska2026,
author = {Czerwińska, Karolina and Bielawska, Anna and Radziejewska, Iwona},
title = {Kaempferol, Luteolin, Astragalin, and Tiliroside Change Glycoform Expression in HT-29 and DLD-1 Colon Cancer Cells},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1676},
doi = {10.3390/biom16111676}
}
EUVIMED